Transthyretin Amyloidosis Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Transthyretin Amyloidosis Treatment Market Analysis

The Transthyretin Amyloidosis Treatment Market size is estimated at USD 5.30 billion in 2024, and is expected to reach USD 10.90 billion by 2029, growing at a CAGR of 15.40% during the forecast period (2024-2029).

The transthyretin amyloidosis treatment market is expected to grow significantly due to the growing geriatric population and risk factors for the amyloid light chain (AL), increasing research and developments (R&D), and raising public disease awareness. Aging is associated with changes in the body's protein structure and function. Transthyretin, a transport protein primarily produced in the liver, undergoes misfolding over time. This misfolding is a critical factor in the development of amyloidosis, where abnormal protein aggregates form and accumulate in tissues, leading to organ dysfunction.

In addition, plasma cell dyscrasia, a condition characterized by abnormal plasma cells, is a known risk factor for amyloid light chain (AL) amyloidosis, a subtype of amyloidosis. The risk of developing plasma cell dyscrasias, including conditions like multiple myeloma, tends to increase as older individuals are more susceptible to abnormalities in plasma cell function and proliferation. For instance, according to the data published by the WHO in October 2023, the population of individuals aged over 65 years is estimated to outnumber those under the age of 15 years in the WHO European region by 2024. This shows a significant number of people in the aging population compared to those of a young age, which may increase the risk of amyloid light chain (AL) amyloidosis, thereby boosting market growth over the study period.

Furthermore, increasing R&D and growing disease awareness are other significant factors driving the growth of the transthyretin amyloidosis treatment market. Pharmaceutical and biotechnology firms are committing substantial resources to R&D to pioneer innovative and targeted treatments for transthyretin amyloidosis. For instance, in February 2024, AstraZeneca reported positive high-level results from the Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Similarly, in March 2023, Ionis Pharmaceuticals reported the acceptance of a New Drug Application (NDA) for eplontersen, an antisense medicine for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) by the Food and Drug Administration. These instances show the growing R&D on treating transthyretin amyloidosis, which is expected to have significant growth in the market over the forecast period.

Therefore, the growing geriatric population, risk factors for AL, and increasing R&D activities are some major factors driving the growth of the transthyretin amyloidosis treatment market. However, the high cost associated with this treatment is expected to restrain the market over the forecast period.

Transthyretin Amyloidosis Treatment Market Trends

The Hereditary Transthyretin Amyloidosis Segment is Expected to Hold a Significant Share Over the Forecast Period

Transthyretin Amyloidosis Treatment Industry Segmentation

As per the scope of the report, transthyretin amyloidosis is a rare disease characterized by the abnormal accumulation of misfolded transthyretin protein, forming amyloid deposits in tissues and organs. Treatment can help manage symptoms, slow disease progression, and improve quality of life.

The transthyretin amyloidosis treatment market is segmented into type, therapy, disease type, distribution channel, and geography. By type, the market is segmented into ATTR-CM (transthyretin amyloid cardiomyopathy) and ATTR-PN (transthyretin amyloid polyneuropathy). By therapy, the market is segmented into targeted therapy and supportive therapy. By disease type, the market is segmented into hereditary amyloidosis, wild-type amyloidosis, and other disease types. Other disease types include AL amyloidosis, AA amyloidosis, and localized amyloidosis. By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and other distribution channels. Other distribution channels include specialty pharmacies and online pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. The report offers market size and forecast in terms of the value (USD) for the above segments.